ZWJ Investment Counsel Inc. raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 35.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,137 shares of the medical instruments supplier’s stock after acquiring an additional 1,885 shares during the period. ZWJ Investment Counsel Inc.’s holdings in Becton, Dickinson and were worth $1,393,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Almanack Investment Partners LLC. acquired a new position in Becton, Dickinson and in the first quarter valued at $105,000. Parkside Financial Bank & Trust boosted its stake in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 9 shares in the last quarter. QCI Asset Management Inc. NY boosted its stake in Becton, Dickinson and by 9.2% in the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock valued at $130,000 after acquiring an additional 60 shares in the last quarter. Financial Architects Inc boosted its stake in Becton, Dickinson and by 8.0% in the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock valued at $142,000 after acquiring an additional 54 shares in the last quarter. Finally, Guardian Life Insurance Co. of America boosted its stake in Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock valued at $150,000 after acquiring an additional 6 shares in the last quarter. Institutional investors own 87.12% of the company’s stock.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total value of $1,178,735.11. Following the completion of the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now directly owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock valued at $15,242,688 over the last ninety days. Company insiders own 1.40% of the company’s stock.

Shares of Becton, Dickinson and Company (BDX) opened at 195.61 on Tuesday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The firm has a market cap of $44.51 billion, a P/E ratio of 56.65 and a beta of 1.06. The stock’s 50 day moving average is $199.25 and its 200 day moving average is $191.52.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period in the previous year, the business posted $2.35 EPS. The company’s quarterly revenue was down 5.1% on a year-over-year basis. On average, equities research analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be issued a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 1.49%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 83.43%.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/19/becton-dickinson-and-company-bdx-shares-bought-by-zwj-investment-counsel-inc.html.

Several equities analysts have issued reports on BDX shares. BidaskClub downgraded shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Bank of America Corporation restated a “buy” rating and issued a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Becton, Dickinson and presently has an average rating of “Buy” and a consensus target price of $196.93.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.